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Proteinases present in myocytesand leukocytes have been
thought to contribute to ischemic myoceUular death. To
test this concept, the effects of three potent proteinase
inhibitors (Ieupeptin, antipain and pepstatin) on myo-
cardial infarct size were investigated. In the first exper-
iment, rats received leupeptin intravenously (in either a
"low" [10 mg/kg] or a "high" [40 mg/kg] dose) 10 min-
utes before coronary artery occlusion; additional doses
were given 2, 4, 6 and 24 hours after occlusion. Low
and high doses were previously shown to reduce pro-
teolysis in ischemic myocardium by 49 and 72%, re-
spectively. Infarct size, measured histologically at 72
hours, did not differ significantly among control (40 ±
2% of left ventricular surface, n =30), low dose (37 ±
5%, n = 21) and high dose (41 ± 3%, n = 23) groups.
In the second experiment, rats received a combina-
tion of leupeptin (40 mg/kg), antipain (20 mg/kg) and
Several studies (1-7) seem to support the concept that cel-
lular proteinases (both those present in myocytes and those
carried by leukocytes) increase ischemic myocellular dam-
age. This hypothesis could be tested by inhibiting the ac-
tivity of cellular proteinases during the development of acute
myocardial infarction and by evaluating the effect of such
inhibition on the extent of ischemic damage, In a previous
study (8), we noted that proteolysis in ischemic rat myo-
cardium can be almost completely suppressed by in vivo
administration of leupeptin, antipain and pepstatin, three
From the Section on Experimental Physiology and Pharmacology, Car-
diology Branch, National Heart, Lung, and Blood Instttute, Nattonal In-
stitutes of Health. Bethesda, Maryland. This paper was presented in part
at the 54th Scientific Sessions of the Amencan Heart Association Mcenng.
Dallas, Texas, November 1981 Manuscript received December 28, 1982;
revised manuscnpt received May 9, 1983, accepted May 13, 1983
*Present address and address for repnnts: Roberto Bolli, MD. Section
of Cardiology, Baylor College of Medicme and The Methodist Hospital.
6535 Fannin M.S. F-905, Houston, Texas 77030.
© 1983 by the Amencan College of Cardiology
pepstatin (5 mg/kg) intravenously before and 2 and 4
hours after coronary occlusion. This treatment was pre-
viously shown to decrease proteolysis in ischemic regions
by 88% at 15 minutes and by 72% at 6 hours of occlu-
sion. Infarct size, determined at 6 hours by incubating
heart slices in triphenyl-tetrazolium-chloride, was not
significantly different between control (44 ± 3% of left
ventricular weight, n = 23) and treated (48 ± 2%, n
= 30) animals. Thus, despite almost complete suppres-
sion of proteolysis throughout the development of irre-
versible injury, the ultimate extent of ischemic damage
was not reduced.
These results indicate that proteolysis occurring dur-
ing the early phase of acute myocardial infarction does
not in itself cause ischemic myocellular death. Accord-
ingly, proteinase inhibition soon after coronary occlusion
does not appear to be an infarct-sparing mechanism.
recently developed proteinase inhibitors (9). The present
study was undertaken to investigate whether in vivo phar-
macologically induced suppression of proteolysis reduces
the size of acute myocardial infarction in rats.
Methods
Experiments were performed in male Sprague-Dawley
rats (230 to 270 g).
Evaluation of the hemodynamic effects of proteinase
inhibitors. Preliminary experiments were carried out to as-
sess whether the doses of ieupeptin, antipain and pepstatin,
which suppress proteolysis in ischemic myocardium, sig-
nificantly alter heart rate and systemic arterial pressure, two
important determinants of infarct size. To evaluate the
hemodynamic effects of leupeptin, five rats were anesthe-
tized with ether. The femoral artery was cannulated with a
PE 10 catheter and mean arterial pressure measured with a
0735-1097/83/$300
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Figure 2. Response of heart rate (HR, open squares) and systolic
(open circles), diastolic (closed squares) and mean (closed cir-
cles) systemic arterial pressure (SAP) to four intravenous (i.v.)
injections of proteinase inhibitors . Values are mean ± standard
error of the mean . ANT = antipain; LPT = leupeptin; PEP =
pepstatin.
P23DbStatham transducer. Lead IIof the electrocardiogram
was continuously monitored. Heart rate and mean arterial
pressure were recorded before and for 5 minutes after in-
travenous injection of leupeptin (40 mg/kg in 0.25 ml of
normal saline solution) (Fig. I).
A second experiment was performed to evaluate the
hemodynamic effects of the combination of leupeptin, an-
tipain and pepstatin . In this experiment, rats were studied
in the conscious state. Under ether anesthesia, a PE 50
cannula was introduced into the femora l artery in six rats.
Phasic and mean arterial pressures were measured with a
P23Db Statham transducer. After recovery from anesthesia,
recordings were taken under basal conditions and I and 10
minutes after each intravenous injection of proteinase in-
hibitors (Fig. 2). Each injection was performed under ether
anesthesia, from which the animals recovered within 2 to
3 minutes.
Evaluation of the effect of leupeptin on myocardial
infarct size. Before coronary artery occlusion, rats were
randomly given either 0.9% saline solution (control group),
leupeptin in " low" dose or leupeptin in "high" dose. Be-
cause the effect of leupeptin on proteolysis lasts at least 2
hours (8), this agent was readministered at 2, 4 and 6 hours















Figure 1. Response of mean systemic arterial pressure (SAP,
dashed line) and heart rate (HR, continuous line) to intravenous
(i.v.) leupeptin, 40 mg/kg. Values are mean ± standard error of
the mean. bpm = beats per minute.
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proteolysis during the early phase of myocardial infarction
when irreversible damage develops. Additional doses were
given at 24 hours to prevent possible rebound increases in
proteolysis. The details of the treatment are illustrated in
Figure 3. The technique to produce coronary artery occlu-
sion in rats has been described previously (8,10).
Seventy-two hours after coronary occlusion, animals were
reanesthetized with ether. The heart was excised and fixed
in [0% phosphate-buffered formalin for 24 hours. The ven-
tricle was sectioned into four slices, each 2 to 2.5 mm thick,
from apex to base in a plane parallel to the atrioventricular
groove. The slices were then embedded in paraffin. Sec-
tions, 6p. thick, were cut from the middle of each slice (so
that they were evenly distributed along the apical-basal axis),
mounted on 3 X 2 inch (7.6 x 5. [ ern) glass slides and
stained with hematoxylin-eosin. The histologic sections of
all four slices from each heart were projected onto a screen
at a lfl- fold magnification and the following measurements
were taken in each section: I) the area of normal and in-
farcted left ventricular myocardium (determined by plani-
metry), 2) the length of the arcs of the endocardial and
epicardialcircumference of the left ventricle underlying the
normal and the infarcted myocardium, and 3) the average
thickness of normal and infarcted left ventricle. This latter
variable was determined by measuring thickness at six points,
obtained by dividing the left ventricular cavity into six 600
angles (usuallythree pointswerewithin the normal andthree
within the infarcted myocardium) .
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From these measurements . the size of the infarct was
calculated as percent of the total left ventricular mass and
of the total left ventricular surface. The fanner detenni-
nation was made by averaging the percent infarcted area in
each of the four slices. The latterwasestimatedby averaging
the lengths of the endocardial and epicardial arcs corre-
sponding to infarcted myocardium. The resulting value was
expressed as percent of the average between total endocar-
dial and epicardialcircumference of each slice. The percents
of the four slices were then averaged to give the fraction of
the left ventricular surface that was infarcted. Because the
thickness of the infarct in the rat decreases after the first
day of coronaryocclusionwhilethe surface remains constant
(10), infarct size at 3 days is underestimated whenexpressed
as percent of left ventricular mass and is more accurately
estimated when related to left ventricular surface (0). Forty-
one hearts were analyzed by two independent observers; the
interobserver variability was less than 5% (correlation coef-
ficient = 0.93).
The degree of thinning of the infarct was measured by
two methods: I) in each slice the average thickness of normal
and infarcted ventricle was obtained (see earlier) and the
ratio of normal to infarct was calculated; the ratios of the
four slices were then averaged; and 2) the thickness of the
Figure 3. Protocols of the experiment on the effect of leupeptin
on myocardial infarct size. Upper panel. High dose of leupeptin;
Lower panel. Low dose of leupeptin. i.m. = intramuscularly;
i.v. = intravenously .
infarct was measured at its thinnest point in any of the four
sections.
The only rats excluded from the final analysis were those
with either no histologic evidence of necrosis or a small
subepicardial area of necrosis at the level of the coronary
ligature not extending to either of the adjacent slices (thus
the necrotic area was < 2.5 mm in the apical-basal axis).
Lack of infarct in these animals was assumed to result from
failure to occlude the coronary artery. Failure to occlude
the coronary artery (as indicatedby lack of infarct) occurred
in 9% of the control group, 17% of the low dose group and
12% of the high dose group. These values were not statis-
tically different.
Evaluation of the effect of leupeptin, antipain and
pepstatin on myocardial infarct size. Because the com-
bination of leupeptin, antipain and pepstatin appeared more
effective than leupeptin alone in inhibiting proteolysis in
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ischemic myocardium (8), we performed an additional ex-
periment to evaluate the influence of this combination on
infarct size. Rats were randomized to control or treated
groups. The treatment is illustrated in Figure 4. Six hours
after coronary occlusion, rats were reanesthetized with ether.
The heart was excised and cut into four slices in a plane
parallel to the atrioventriculargroove. To delineateinfarcted
myocardium, slices were incubated for 45 minutes in 1%
triphenyl-tetrazolium-chloride at 37°C . This agent stains vi-
able dehydrogenase-containing myocardium dark red (II) ,
while the necrotic myocardium remains unstained and ap-
pears as a white-gray zone (Fig. 5).
Ultrastructural (12-14) and histochemical (15) studies
strongly suggest that, in the rat model, the infarct virtually
achieves its eventual size by 6 hours of coronary occlusion.
To confirm this conclusion, in nine rats (five control and
four treated) the size of the infarcted region (determined by
triphenyl-tetrazolium-chloride) was compared with that of
the ischemic region. The latter was delineated by intrave-
nous injection of 1.0 ml of black ink just before sacrifice.
Perfused myocardium was stained black while the ischemic
region remained pink. After the heart was cut into four
Figure 4. Protocol of the experiment on the effect of antipain
(ANT), leupeptin (LPT) and pepstatin (PEP) on myocardial infarct
size. i.p. = intrapentoneaIly; i.v. = intravenously; TIC = tri-
phenyl-tetrazolium-chloride.
transverse slices, the border between stained and unstained
myocardium was marked with shallow cuts on each slice
(Fig. 5). Slices were then incubated in triphenyl-tetrazo-
lium-chloride as described previously.
After staining with triphenyl-tetrazolium-chloride, the right
ventricle and the atria were excised and the slices weighed.
Only rats that had no tetrazolium-negativemyocardiumwere
excluded from the final analysis. In these animals, failure to
occlude the coronary artery was assumed to have occurred.
The percent of control and treated rats excluded according
to such criteria was similar (15 and 20%, respectively).
Infarct size was estimated by three techniques. In the
first technique, slices were photographed, transparencies
were projected onto paper and necrotic and surviving por-
tions were traced. Each area was measured by planimetry,
and the infarct mass weight was expressed as a fraction of
the weightof each slice. Total infarct weight was calculated
as percent of the left ventricle. In the animals in which the
ischemic region was delineated by ink injection, the weight
of the ischemic region was calculated as percent of the left
ventricle in a similar manner. In these animals, infarct weight
was also expressed as percent of the weight of the ischemic
region. In the second technique, infarct size was expressed
as percent of the left ventricular surface by a procedure
analogous to that described for the leupeptin experiment.
Finally, a third measure of infarct size was obtained by
excising the necrotic portion of each slice. Both infarcted
and normal myocardium were weighed and infarct wet weight
was expressed as percentof total left ventricular wet weight.
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The reproducibility of planimetric estimate s of infarct size
was excellent: the difference between values obtained by
two observers was less than 5% (r = 0.95 , n = 2\).
Statistical analysis. All values are expre ssed as mean
± standard error of the mean. Difference s between mean
values of two groups were evaluated by unpaired Student's
( tests. One way analysis of variance was used for com-
parisons involving more than two groups. Incidence of events
was analyzed by chi-square test using Yates' correction for
continuity. Probability (p) values were considered signifi-
cant if they were less than 0 .05 .
Results
Hemodynamic effects of proteinase inhibitors. Leu-
peptin in the high dose (40 mg/kg intravenously) produced
a transient drop in blood pressure lasting less than 5 minutes
(Fig . I) . Heart rate was not affected. Thu s, this agent did
not produce any significant sustained hemodynamic effect.
Figure 2 depicts the hemodynamic effects of the combi-
nation of leupeptin , antipain and pepstatin given in doses
identical to those emplo yed in the infarct size study . Rats
were studied in the conscious state . The first set of mea-
surements was taken under basal conditions and the second
under ether anesthesia before the first injection . Ether low-
ered blood pressure , an effect that might have contributed
to the fall in blood pressure observed I minute after each
injection , but pressure returned to baseline levels within 10
minutes after the injection. Heart rate did not change sig-
nificantly . No cumul ative effect was produced by subse-
quent injections, so that at the end of the experiment hemo-
dynamic values were unchanged from the baseline levels.
Effects of leupeptin on mortality and infarct size (Ta-
ble I). Overall mortality dur ing the 3 days of coronary
occlusion was not significantly differe nt among con trol, leu-
peptin low dose and leupeptin high dose groups. Only one
subendocardial infarct was observed (in the control group) .
Incidence of small infarcts ( < 20% of left ventricular sur-
face) was also not significantly different in the three groups,
excluding a selective beneficial effect of lcupeptin on smaller
infarcts. Infarct size, expressed as percent of either left
ventricular weight or left ventricular surface, was similar in
Figure 5. A typicalexampleof myocardial infarctionasdelineated
by triphcnyl-tetrazo lium-chloride at 6 hours of occlusion. Heart
sections are numbered 1 to 4 from the apex (a = apical aspect)
to the base (b = basal aspect) of the heart. The white region is
tetrazolium-negative and, therefore, infarcted, while the dark reo
gion is tetrazolium-positive and viable. Pins indicate the borders
of the ischemic region, demarcated by intravenous injection of
black ink immediately before sacrifice. Note that virtually all of
the ischemic region is infarcted.
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contro l rats and in rats given low and high doses of leu-
peptin . Even when rats that exhibited no infarct were in-
cluded in the final analysis, no significant difference was
observed between control and treated groups.
Leupeptin did not affect the degree of thinning of the
infarct, The ratio of the average thickness of normal tissue
to that of the infarct was 1.35 ± 0.04 in the control group,
1.29 ± 0.06 in the low dose group and 1.34 ± 0 .04 in
the high dose group. The thinnest point of the infarct mea-
sured 0.70 ± 0.02 mm in control rats, 0.80 ± 0.05 mm
in the low dose group and 0.75 ± 0.03 mm in the high
dose group. Thus, suppressio n of proteolysis early in the
course of myocardial infarction did not result in significant
thinning or expansion of the infarct 3 days after occlusion.
The degree of thinning, estim ated by measuring the thinnest
point of the infarct , was significantly correlated with infarct
size exp ressed as percent of left ventricular surface (r =
0.63, p<O .OO I); this relation could be described by the
equation: infarct size = 1.9 1 - 0.012 x thinnest
measurement.
Effects of leupeptin, antipa in and pepstatin on mor-
tality and infarct size. Mortality was similar in control and
treated groups (Table I). Infarct size , expressed either as
percent of left ventricular weight measured directly. as per-
cent of left ventricular weight estimated by planimetry or as
percent of left ventricular surface estimated by planimetry ,
was not significantly differe nt between control and treated
groups (Table I). Even when rats exhibiti ng no tetrazolium-
negative (that is, infarcted) myocardium were included in
the final analysis , the results were similar in the two groups.
Infa rc t size vers us ischemic region after 6 hours of
corona ry ar tery occlusion. In nine rats (five control and
four treated) sacrificed at 6 hours of ischemia, the infarc ted
region was determined by triphenyl-tetrazolium-chloride and
the ischemic region was delineated by intrave nous ink in-
jection. The weight of these two regions, dete rmined by
planimetry, was almost identical in both control and treated
animals (Fig . 5, Tabl e 2).
Discussion
Modeling considerations. Two variations of the rat model
of acute myocardial infarct ion were used in this study . In
the experiment in which leupeptin alone was administered,
infarct size was determined by planimetry of histologic slides
3 days after coronary artery occlusion. This technique, used
at 2 days of occlusion , has been able to detect infarct size
reduction by a variety of interventions, including reserpine
Table 1. Effects of Proteinase Inhibitors on Mortality and Myocardial Infarct Size
Mortality rate
Small infarcts
«20 % of LV surface)
Infarct size
(% of LV mass)
Infarct size
(% of LV surface)
Leupeptm Alone
Leupeptin
Control "Low" Dose " High" Dose
(n = 30) (n = 21) (n = 23)
10 (33 %) 7 (33'k) 9 (39%)
3 (10%) 4 ( 19%) 2 (9%)
34 ± 2 33 ± 4 36 ± 2






Combination of Lcupcptm, Antipain and Pepstann
Control LPT + ANT + PEP
(n = 23) (n = 30) p
Mortality rate 5 (22%) 7 (23%)
Infarct size 44 ± 3 48 ± 2 NS
(% of LV mass, direct measurement)
Infarct size 48 ± 3 51 ± 2 NS
(% of LV mass, planimetry)
Infarct size 46 ± 3 48 ± 2 NS
(% of LV surface)
Values are mean ± standard error of the mean.
ANT = antipain; LPT = leupeptin; LV = left ventricular; NS = not significant; p = probability (versus control); PEP = pepstatin.
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Table 2. Infarct Size Versus Ischemic Region After 6 Hours of
Coronary Artery Occlusion
Control LPT + ANT + PEP
(n = 5) (n = 4) P
Infarct size 45 ± 2 44 ± 4 NS
(% of LV mass)
Ischemic region 47 ± 4 46 ± 4 NS
(% of LV mass)
Infarct size 95 ± 3 96 ± 3 NS
(% of ischemic region )
Values are mean ± stand ard error of the mean Abbrevianons as in
Table I .
(16), methylprednisolone (16), hydrocortisone (16), cobra
venom factor (16), hyaluronidase (16), ibuprofen (17), ex-
ercise (18) and labetalol (19) . We determined infarct size
at 3 days to have an even better histologic demarcation of
the necrotic region without the excessive thinning that has
been reported to occur at a later stage (10 ).
In the experiment with the combination of proteinase
inhibitors. infarct size was measured at 6 hours of coronary
artery occlusion, The rationale for assessing the extent of
necrosis after 6 hours of ischemia was to rule out the pos-
sibility that an early beneficialeffect of proteinase inhibitors
on ischemic damage might have been missed at 3 days after
coronary occlusion because of the progressive decrease in
tissue concentration of these agents. Such a possibility must
be considered in view of the fact that leupeptin, antipain
and pepstatin have short plasma half-lives (approximately
2 hours) (20). We have previously shown (8) that the re-
peated treatments used in this experiment result in contin-
uous suppression of proteolysis, which is already evident
at 15 minutes and is still present at 6 hours of occlusion
(time of sacrifice in this protocol). These experimental con-
ditions appear extremely favorable for the detection of any
beneficial effect of proteolysis inhibition on ischemic dam-
age, even if such an effect consisted of a mere delay of
necrosis.
The validity of determining infarct size at 6 hours of
ischemia requires that the process of myocellular death be
complete, or almost complete, at this time. Ultrastructural
(12-14 ) and histochemical (15 ) studies indicate that the
evolution of the infarct is very rapid in the rat model, and
strongly suggest that it is virtually complete by 6 hours of
coronary occlusion. This speculation is substantiated by two
observations in the present study: I) virtually all of the
ischemic region (determined by intravenous ink injection)
was unstained by triphenyl-tetrazolium-chloride (and thus
was necrotic) at 6 hours both in control and in treated rats;
and 2) in the control groups, the surface of the infarct, as
determined by planimetry, was similar at 6 hours (46 ±
3% of the left ventricle) and at 3 days (40 ± 2%). Therefore,
the lack of an infarct-sparing action of proteinase inhibitors
at 6 hours of ischemia indicates that these agents failed to
affect the eventual extent of ischemic damage.
The virtual identity between ischemic region and infarct
in the rat model implies that infarct size should be relatively
uniform if coronary occlusion is performed at similar an-
atomic sites. Indeed, the variability in infarct size was small
in both of our experiments, as indicated by the narrow
standard error of the mean in the control groups (± 2% in
the 3 day experiment and ± 3% in the 6 hour experiment).
These considerations emphasize that even small reductions
in ischemic necrosis would have been detected in the present
study. The likelihood of a type II error in our conclusions
is minimal also because consistently negative results were
obtained with the two methods used to express infarct size
in the 3 day experiment (percent of left ventricular mass
and of left ventricular surface) and with the three methods
used in the 6 hour experiment (percent of left ventricular
weight measured directly, of left ventricular weight esti-
matedby planimetryand of left ventricularsurfaceestimated
by planimetry).
Significance of proteo lysis in acute myocardial in-
farction. If cellular proteinases are biologically important
in the production of ischemic cell death, even by selective
digestion of key substrates, inhibition of proteolysis in vivo
during the development of irreversible damage would be
expected to limit the extent of such damage. In the present
study, the administration of proteinase inhibitors in doses
that markedly suppress proteolysis in ischemic myocardium
consistently failed to reduce infarct size. Thus, no beneficial
effect on ischemic damage was produced by either low or
high doses of leupeptin, which reduce proteolysis in isch-
emic regions by 49 and 72%, respectively (8). Likewise,
no appreciable reduction of ischemic necrosis was observed
with the combination of leupeptin, antipain and pepstatin,
which inhibits protein breakdown almost completely
throughout the phase of acute coronary occlusion during
which myocellular death develops (- 88% at 15 minutes
and - 72% at 6 hours [8]). The lack of any beneficialeffect
of proteinase inhibitors cannot be ascribed to deleterious
changes in heart rate or blood pressure, or both, because
these agents did not significantly affect hemodynamic val-
ues. The similarity in mortality rates between control and
treated groups excludes the possibility that suppression of
proteolysis improved survival after acute coronary occlu-
sion, an effect that theoretically might interfere with the
detection of an infarct-sparing action.
The results of this study and those of our previous in-
vestigations (8.21) indicate that the activity of cellular pro-
teinases during acute ischemia docs not contribute in a bio-
logicallyimportantwayto Irreversibledamage. Accordingly.
the current concepts regarding the mechanisms of ischemic
myocellular death need to be reassessed. Activation of pro-
teolytic enzymes (preexisting in the myocytes or carried by
leukocytes accumulating in the ischemic zone) is unlikely
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to be a significant causal factor in this process. The early
release of lysosomal proteases whose significance for cel-
lular integrity has been thus far debated (6), appears to be
a consequence, rather than a cause , of ischemic damage.
In light of our results , it seems important that future studies
of the mechanisms of ischemic myocellular death focus on
other phenomena, such as mitochondrial and sarcolemmal
damage (5).
Implications for the mechanisms of action of infarct-
sparing interventions. Our data have implications for the
mechanisms of action of several infarct-sparing interven-
tions. The salutary effect s on ischemic myocardium of pro-
teinase inhibitors, such as aprotinin (22), and of " lysoso-
mal-stabili zing" agents, such as corticosteroids (23,24) and
ibuprofen (17,25), have been generally attributed to reduc-
tion in the activit y of cellular, and particularly lysosomal ,
proteinases (22-27). Because leukocytes contain abundant
proteinases, a similar mechanism has been recently invoked
to explain the observation that infarct size is markedly re-
duced by depletion of white blood cells (7). The failure of
near complete suppression of proteolys is to reduce ischemic
damage in the present study, however, implies that pro-
teinase inhibition soon after coronary occlusion does not
represent an important infarct-sparing mechanism. Accord-
ingly, the beneficial effects of these interventions are likely
to depend on other actions (for example, inhibition of com-
plement, reduced activity of phospholipases or reduced re-
lease of activated oxygen products).
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